Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
Catheter Cardiovasc Interv ; 95(5): 1051-1056, 2020 04 01.
Article in English | MEDLINE | ID: mdl-31478304

ABSTRACT

OBJECTIVES: This multicenter retrospective study of the initial U.S. experience evaluated the safety and efficacy of temporary cardiac pacing with the Tempo® Temporary Pacing Lead. BACKGROUND: Despite increasing use of temporary cardiac pacing with the rapid growth of structural heart procedures, temporary pacing leads have not significantly improved. The Tempo lead is a new temporary pacing lead with a soft tip intended to minimize the risk of perforation and a novel active fixation mechanism designed to enhance lead stability. METHODS: Data from 269 consecutive structural heart procedures were collected. Outcomes included device safety (absence of clinically significant cardiac perforation, new pericardial effusion, or sustained ventricular arrhythmia) and efficacy (clinically acceptable pacing thresholds with successful pace capture throughout the index procedure). Postprocedure practices and sustained lead performance were also analyzed. RESULTS: The Tempo lead was successfully positioned in the right ventricle and achieved pacing in 264 of 269 patients (98.1%). Two patients (0.8%) experienced loss of pace capture. Procedural mean pace capture threshold (PCT) was 0.7 ± 0.8 mA. There were no clinically significant perforations, pericardial effusions, or sustained device-related arrhythmias. The Tempo lead was left in place postprocedure in 189 patients (71.6%) for mean duration of 43.3 ± 0.7 hr (range 2.5-221.3 hr) with final PCT of 0.84 ± 1.04 mA (n = 80). Of these patients, 84.1% mobilized out of bed with no lead dislodgment. CONCLUSION: The Tempo lead is safe and effective for temporary cardiac pacing for structural heart procedures, provides stable peri and postprocedural pacing and allows mobilization of patients who require temporary pacing leads.


Subject(s)
Cardiac Pacing, Artificial , Cardiac Surgical Procedures , Pacemaker, Artificial , Perioperative Care/instrumentation , Aged , Aged, 80 and over , Cardiac Pacing, Artificial/adverse effects , Cardiac Surgical Procedures/adverse effects , Equipment Design , Female , Heart Rate , Humans , Male , Patient Safety , Perioperative Care/adverse effects , Registries , Retrospective Studies , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome , United States , Ventricular Function, Right
2.
Catheter Cardiovasc Interv ; 96(1): 219-224, 2020 07.
Article in English | MEDLINE | ID: mdl-31696617

ABSTRACT

Percutaneous patent foramen ovale (PFO) closure is recommended for secondary prevention of paradoxical embolism through a PFO. In the United States, two Food and Drug Administration-approved PFO closure devices are currently available, and the choice depends on operator preference and PFO anatomy. Although these devices are easy to implant, there are several potential complications. As opposed to the Amplatzer PFO Occluder, there has been no published case of atrial erosion with Gore closure devices. This report describes two cases of pericardial tamponade due to perforation of the atrial wall induced by a wire frame fracture of the Gore Helex and Cardioform devices.


Subject(s)
Cardiac Catheterization/adverse effects , Cardiac Catheterization/instrumentation , Cardiac Tamponade/etiology , Foramen Ovale, Patent/therapy , Heart Atria/injuries , Heart Injuries/etiology , Prosthesis Failure , Septal Occluder Device , Adult , Cardiac Tamponade/diagnostic imaging , Cardiac Tamponade/surgery , Device Removal , Female , Foramen Ovale, Patent/complications , Foramen Ovale, Patent/diagnostic imaging , Heart Atria/diagnostic imaging , Heart Atria/surgery , Heart Injuries/diagnostic imaging , Heart Injuries/surgery , Humans , Middle Aged , Prosthesis Design , Treatment Outcome
3.
Am J Emerg Med ; 32(3): 287.e5-8, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24176590

ABSTRACT

Certain acute coronary syndrome electrocardiographic (ECG) patterns, which do not include ST-segment elevation, are indicative of acute coronary syndrome caused by significant arterial occlusion; these patterns are, of course, associated with significant risk to the patient and mandate a rapid response from the health care team. One such high-risk ECG pattern includes the association of the prominent T wave and J-point depression producing ST-segment depression seen in the precordial leads coupled with ST-segment elevation in lead aVr. This ECG presentation is associated with significant left anterior descending artery obstruction. We report the case of a patient with this ECG presentation who progressed over a very short time to ST-segment elevation myocardial infarction of the anterior wall.


Subject(s)
Electrocardiography , Myocardial Infarction/diagnosis , Humans , Male , Middle Aged , Myocardial Infarction/physiopathology
4.
Am Heart J ; 150(4): 796-9, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16209984

ABSTRACT

BACKGROUND: The active metabolite of clopidogrel binds the P2Y12 ADP receptor on the platelet surface via a disulfide bond. N-Acetylcysteine (NAC) is able to reduce disulfide bonds. We postulated that NAC might reverse clopidogrel's effect on platelets. METHODS: Two groups of patients were investigated. Group 1 included 11 patients with stable coronary disease who, after discontinuation of aspirin, received 14 days of clopidogrel, 75 mg/day. Bleeding time and whole-blood platelet aggregometry (with 5 micromol/L ADP) were compared before and after the 14 days. Patients were then treated with 6 g of NAC orally, followed by repeat measurement of bleeding time and aggregometry. In group 2, 14 patients were treated with clopidogrel (300 mg) and aspirin before a percutaneous coronary intervention. Blood was drawn 22 +/- 3 hours later and divided into 2 samples. One was sent immediately for platelet-rich plasma aggregometry (using 5 and 2 micromol/L ADP, collagen, and arachidonic acid as agonists), thromboelastography, and aggregometry using the Plateletworks assay (Helena Laboratories, Beaumont, Tex). The other sample was treated with NAC (500 mg/L), after which these same platelet function tests were performed. RESULTS: In group 1, NAC therapy did not significantly change the bleeding time or results of aggregometry. In group 2, neither aggregometry nor the Plateletworks assay suggested reversal of inhibition by NAC. CONCLUSIONS: These studies reveal that a large dose of NAC does not reduce inhibition of platelet aggregation by clopidogrel in vitro or in vivo.


Subject(s)
Acetylcysteine/pharmacology , Platelet Aggregation Inhibitors/pharmacology , Platelet Aggregation/drug effects , Ticlopidine/analogs & derivatives , Clopidogrel , Drug Interactions , Humans , Prospective Studies , Ticlopidine/antagonists & inhibitors
5.
Am J Cardiol ; 96(4): 512-4, 2005 Aug 15.
Article in English | MEDLINE | ID: mdl-16098302

ABSTRACT

We report on the incidence of adverse cardiac events in 350 patients who underwent noncardiac surgery within 2 months of successful balloon angioplasty (BA) at our institution between 1988 and 2001. Three patients died perioperatively (n = 1) or had myocardial infarction (n = 2) (0.9%, 95% confidence interval [CI] 0.2% to 2.5%), which is a lower incidence than that reported for patients undergoing noncardiac surgery after stenting (3.9% to 32%). One patient died, and 2 had a nonfatal myocardial infarction. All 3 (1.6%, 95% CI 0.3% to 4.6%) were among the 188 patients who underwent surgery within 2 weeks of BA. Repeat target vessel revascularization was performed in 10 patients (2.9%, 95% CI 1.4% to 5.2%): in 3 (1.6%, 95% CI 0.3% to 4.6%) of 188 patients who underwent surgery within 2 weeks of BA and in 7 (5.1%, 95% CI 2.1% to 10.2%) of 138 patients who underwent surgery within 3 to 7 weeks of BA. Therefore, in patients in whom percutaneous coronary revascularization is required before noncardiac surgery, BA appears to be safe, especially in patients who need to undergo surgery early after percutaneous coronary intervention.


Subject(s)
Angioplasty, Balloon, Coronary , Digestive System Surgical Procedures , Myocardial Ischemia/therapy , Orthopedic Procedures , Urogenital Surgical Procedures , Aged , Coronary Angiography , Endosonography , Female , Follow-Up Studies , Humans , Male , Myocardial Ischemia/diagnosis , Myocardial Ischemia/mortality , Perioperative Care/methods , Retrospective Studies , Survival Rate , Time Factors , Treatment Outcome
6.
J Autoimmun ; 23(4): 345-52, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15571928

ABSTRACT

BACKGROUND: Autoantibodies to oxidized LDL (anti-oxLDL) have been found in the serum of patients with coronary artery disease (CAD). This study was designed to compare the differences in anti-oxLDL titers and isotypes in unstable and stable angina patients and to correlate these results with known markers of active inflammation in CAD. METHODS: Thirty patients from a tertiary referral general hospital with documented CAD were studied. Anti-oxLDL IgG titers and its isotypes, high sensitivity C-reactive protein (hsCRP) and serum amyloid A (SAA) were measured. RESULTS: The anti-oxLDL IgG titer was lower (p=0.03) in the unstable angina group compared to the stable angina patients (0.084+/-0.102 OD versus 0.195+/-0.149 OD, respectively). The predominant IgG isotype in both groups was IgG2. IgG4 was significantly higher (0.270+/-0.146 OD, p=0.04) in the unstable angina group versus patients with stable angina (0.198+/-0.019 OD). There was a significant inverse correlation between anti-oxLDL and hsCRP and SAA in this sample population (R=0.37, p<0.05 and R=0.36, p<0.05, respectively). CONCLUSION: Patients with unstable angina have lower levels of anti-oxLDL IgG in the acute setting of CAD. Plaque instabilization does not seem to acutely modify the isotype subsets of anti-oxLDL IgG in these patients.


Subject(s)
Angina Pectoris/immunology , Angina, Unstable/immunology , Autoantibodies/blood , Coronary Artery Disease/immunology , Lipoproteins, LDL/immunology , Adult , Aged , Angina, Unstable/diagnosis , Biomarkers/blood , C-Reactive Protein/analysis , Female , Humans , Immunoglobulin G/blood , Immunoglobulin Isotypes/blood , Male , Middle Aged , Recurrence
7.
Am Heart J ; 148(3): 501-6, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15389239

ABSTRACT

PURPOSE: The purpose of the current study was to determine whether there is any incremental benefit to routine intravascular ultrasound (IVUS) guidance of percutaneous coronary intervention. METHODS AND RESULTS: We compared the outcome of 796 patients who underwent an IVUS study (IVUS group) during the index stent procedure with 8274 patients who did not have an IVUS study (angiography group). The primary end point was the composite end point of death, myocardial infarction, or ischemia-driven target vessel revascularization within 9 months of the index stent procedure. There were statistically significant differences in multiple procedural characteristics. Most importantly, those patients who underwent an IVUS study had a larger postprocedural minimal lumen diameter and smaller postprocedural percent diameter stenosis. However, there was no significant difference between the IVUS group and the angiography group with respect to the primary end point (RR 1.10, 95% CI 0.91, 1.32) or any of the individual clinical end points. Adjustment for multiple clinical and procedural characteristics did not significantly alter these findings. CONCLUSIONS: These data suggest that the routine performance of IVUS during stent placement influences the performance of the procedure, as judged by differences in procedural characteristics, but does not improve clinical outcome at 9 months.


Subject(s)
Angioplasty, Balloon, Coronary/methods , Coronary Disease/therapy , Stents , Ultrasonography, Interventional , Coronary Angiography , Coronary Disease/mortality , Disease-Free Survival , Double-Blind Method , Female , Humans , Male , Middle Aged , Myocardial Infarction , Risk , Treatment Outcome
8.
Catheter Cardiovasc Interv ; 63(2): 152-7, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15390249

ABSTRACT

The objective of this study was to evaluate the safety and efficacy of cutting balloon angioplasty (CBA) for the treatment of in-stent restenosis prior to intracoronary brachytherapy (ICB). Cutting balloon angioplasty may reduce the incidence of uncontrolled dissection requiring adjunctive stenting and may limit "melon seeding" and geographic miss in patients with in-stent restenosis who are subsequently treated with ICB. We performed a retrospective case-control analysis of 134 consecutive patients with in-stent restenosis who were treated with ICB preceded by either CBA or conventional balloon angioplasty. We identified 44 patients who underwent CBA and ICB, and 90 control patients who underwent conventional percutaneous transluminal coronary angioplasty (PTCA) and ICB for the treatment of in-stent restenosis. Adjunctive coronary stenting was performed in 13 patients (29.5%) in the CBA/ICB group and 41 patients (45.6%; P < 0.001) in the PTCA/ICB group. There was no difference in the injury length or active treatment (ICB) length. The procedural and angiographic success rates were similar in both groups. There were no statistically significant differences in the incidence of death, myocardial infarction, recurrent angina pectoris, subsequent target lumen revascularization, or the composite endpoint of all four clinical outcomes (P > 0.05). Despite sound theoretical reasons why CBA may be better than conventional balloon angioplasty for treatment of in-stent restenosis with ICB, and despite a reduction in the need for adjunctive coronary stenting, we were unable to identify differences in clinical outcome.


Subject(s)
Angioplasty, Balloon/methods , Brachytherapy , Coronary Restenosis/therapy , Aged , Angioplasty, Balloon, Coronary , Case-Control Studies , Chi-Square Distribution , Combined Modality Therapy , Coronary Angiography , Coronary Restenosis/etiology , Coronary Restenosis/radiotherapy , Female , Humans , Male , Middle Aged , Registries , Retrospective Studies , Statistics, Nonparametric , Stents , Treatment Outcome
9.
J Thromb Thrombolysis ; 17(1): 11-20, 2004 Feb.
Article in English | MEDLINE | ID: mdl-15277783

ABSTRACT

Thrombosis is an obligatory consequence of all percutaneous vascular interventions. Balloon angioplasty, intravascular stents and other devices routinely used to facilitate dilatation of critical vascular stenoses result in fracture of the intima and exposure of the thrombogenic subendothelium with initiation and perpetuation of platelet activation and aggregation. This not uncommonly results in thrombus formation that may lead to abrupt vessel closure, distal ischemia and tissue infarction, and target organ dysfunction. Fortunately, advances in our understanding of the mechanisms that underlie vascular thrombosis have led to advances in the use of adjunctive pharmacological agents that modulate this pathophysiological response and have led to important reductions in the incidence and severity of thrombotic complications of percutaneous transluminal interventions.


Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Angioplasty, Balloon/adverse effects , Thrombosis/drug therapy , Thrombosis/physiopathology , Humans , Severity of Illness Index , Thrombosis/epidemiology , Thrombosis/prevention & control , Vascular Diseases/drug therapy , Vascular Diseases/physiopathology , Vascular Diseases/surgery
10.
Curr Cardiol Rep ; 6(4): 292-9, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15182607

ABSTRACT

Primary percutaneous coronary intervention (PCI) is the optimal treatment for patients presenting with ST-elevation myocardial infarction (STEMI). But PCI facilities are not widely available, and the majority of patients who receive reperfusion therapy are treated with thrombolytic therapy. However, with significant improvements in the procedural success of PCI, there has been a concomitant reduction in the need for emergency bypass surgery and there is evidence to support primary PCI without on-site cardiac surgical facilities. Others have proposed immediate transfer to a suitable hospital for immediate primary PCI. An alternative treatment strategy is facilitated PCI, which might combine the early benefits of thrombolysis with the higher patency rates and superior clinical outcomes of primary PCI, although this remains unproven. Finally, rescue PCI remains a reasonable treatment option for patients with failed thrombolysis, but there is insufficient evidence to support this option as a preferred treatment strategy for patients with STEMI.


Subject(s)
Angina, Unstable/therapy , Myocardial Infarction/therapy , Patient Transfer , Angioplasty, Balloon, Coronary/statistics & numerical data , Cardiac Care Facilities , Cardiac Catheterization , Humans , Myocardial Infarction/physiopathology , Randomized Controlled Trials as Topic , Regional Medical Programs , Thrombolytic Therapy/statistics & numerical data , Treatment Outcome
11.
Cytokine ; 26(3): 131-7, 2004 May 07.
Article in English | MEDLINE | ID: mdl-15135807

ABSTRACT

BACKGROUND: Atherosclerotic lesions are mainly composed of macrophages and T lymphocytes. Specific T helper type 1 (Th1) cytokines and interferon gamma (IFN-gamma) inducible chemokines have been shown to be present in these lesions, modulating the local immunologic response. To explore whether this increase in Th1 activity could also be detected in circulating cells indicating a systemic activation, we studied the peripheral expression of Th1 cytokines and chemokines in patients with coronary artery disease and controls. METHODS AND RESULTS: Fifty patients with coronary artery disease (25 with unstable angina and 25 with stable angina) and 10 controls were studied. Serum interleukin (IL)-12 and IFN-gamma and the expression of IFN-gamma inducible chemokines IP-10, Mig and their receptor CXCR3 in peripheral cells were analyzed. Serum IL-12 and intracellular expression of IFN-gamma were significantly elevated in patients with unstable angina. An enhanced expression of IFN-gamma chemokines IP-10, Mig and CXCR3 in patients with stable angina was also observed. CONCLUSIONS: This study demonstrates an increased systemic inflammatory activity in patients with coronary heart disease with a predominant Th1 response, particularly in patients with unstable angina, suggesting an important role played by this polarization in plaque formation and rupture.


Subject(s)
Coronary Artery Disease/immunology , Th1 Cells/immunology , Adult , Aged , Aged, 80 and over , Angina Pectoris/metabolism , Female , Humans , In Vitro Techniques , Interferon-gamma/blood , Interleukin-12/blood , Male , Middle Aged , Receptors, CXCR3 , Receptors, Chemokine/metabolism
13.
J Am Coll Cardiol ; 43(8): 1335-42, 2004 Apr 21.
Article in English | MEDLINE | ID: mdl-15093863

ABSTRACT

Intravascular ultrasound (IVUS) has played an integral role in the evolution of interventional cardiology. However, routine IVUS guidance of coronary stent implantation is not supported by a critical reappraisal of the available evidence. Although there is a trend toward a benefit with respect to target lumen revascularization favoring IVUS-guided coronary stent implantation, it is likely that this effect is driven by improved outcomes in small vessels, long coronary stenoses, and possibly saphenous vein graft interventions. No consistent trend in the incidence of death or myocardial infarction is apparent. Furthermore, the safety, efficacy, and effectiveness of IVUS should be taken into account when considering the goals, risks, benefits, and alternatives to such a treatment strategy.


Subject(s)
Angioplasty, Balloon, Coronary/methods , Coronary Artery Disease/therapy , Stents , Ultrasonography, Interventional , Blood Vessel Prosthesis Implantation/methods , Coronary Artery Disease/diagnostic imaging , Humans , Randomized Controlled Trials as Topic
14.
Am Heart J ; 147(3): 463-7, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14999195

ABSTRACT

BACKGROUND: Dual antiplatelet therapy with aspirin and clopidogrel has replaced aspirin and systemic anticoagulation with warfarin as the preferred antithrombotic therapy after percutaneous coronary intervention (PCI) with stent placement. However, a number of patients have indications for all 3 drugs. We sought to determine the frequency and type of hemorrhagic complications in patients who undergo systemic anticoagulation with warfarin while receiving aspirin and clopidogrel after a PCI with stent placement. METHODS: We performed a retrospective analysis of the Mayo Clinic PCI database and identified 66 consecutive patients who were discharged from hospital after PCI between January 2000 and August 2002 (inclusive) receiving a combination of dual antiplatelet therapy (aspirin and clopidogrel) and systemic anticoagulation (warfarin) to determine the incidence of bleeding and other clinical events during the treatment period. RESULTS: Six patients (9.2%; 95% CI, 3.5-19.0) reported a bleeding event; 2 patients required a blood transfusion. No patient died or sustained a myocardial infarction or stent thrombosis. CONCLUSIONS: The risk of bleeding may be increased in patients treated with aspirin, a thienopyridine, and warfarin early after PCI with stent placement.


Subject(s)
Anticoagulants/therapeutic use , Aspirin/therapeutic use , Coronary Disease/drug therapy , Platelet Aggregation Inhibitors/therapeutic use , Stents , Ticlopidine/analogs & derivatives , Ticlopidine/therapeutic use , Warfarin/therapeutic use , Aged , Aged, 80 and over , Angina, Unstable/therapy , Angioplasty, Balloon, Coronary , Anticoagulants/adverse effects , Aspirin/adverse effects , Clopidogrel , Coronary Disease/therapy , Drug Therapy, Combination , Female , Hemorrhage/chemically induced , Humans , Male , Middle Aged , Myocardial Infarction/therapy , Platelet Aggregation Inhibitors/adverse effects , Retrospective Studies , Ticlopidine/adverse effects , Warfarin/adverse effects
15.
Am Heart J ; 147(1): 140-5, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14691432

ABSTRACT

BACKGROUND: Coronary perforation is a serious but uncommon complication of percutaneous coronary intervention (PCI) and is associated with significant morbidity and mortality. METHODS: We performed an analysis of the Mayo Clinic PCI database. Clinical records, procedural reports, and angiographic studies were reviewed. Multiple logistic regression analysis was performed to identify clinical, procedural, anatomic, and angiographic correlates of coronary perforation. RESULTS: A total of 16,298 PCI procedures were performed between January 1990 and December 2001. We identified 95 coronary perforations (0.58%; 95% CI, 0.47-0.71). The incidence of coronary perforation varied with time. Correlates of coronary perforation included the use of an atheroablative device and female sex. Twelve patients (12.6%) sustained an acute myocardial infarction, and cardiac tamponade developed in 11 patients (11.6%). Management strategies included reversal of heparin, pericardiocentesis, placement of a covered stent, and surgical repair. Seven patients died (7.4%). CONCLUSIONS: Coronary perforation during PCI is rare, but is associated with significant morbidity and mortality. The variable frequency of perforation may be explained by temporal variations in the use of atheroablative devices.


Subject(s)
Coronary Artery Disease/therapy , Coronary Vessels/injuries , Wounds, Penetrating/epidemiology , Aged , Angioplasty, Balloon, Coronary , Atherectomy, Coronary/adverse effects , Constriction , Databases, Factual , Female , Humans , Incidence , Male , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Prospective Studies , Protamines/therapeutic use , Regression Analysis , Stents/adverse effects , Wounds, Penetrating/etiology , Wounds, Penetrating/therapy
16.
J Thromb Thrombolysis ; 18(1): 25-30, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15744550

ABSTRACT

INTRODUCTION: While the CURE trial demonstrated the benefits of clopidogrel in acute coronary syndromes, patients receiving glycoprotein IIb/IIIa antagonists were excluded. Given the frequent coadministration of these two medications, we sought to examine their interaction and their combined effect on platelet inhibition. METHODS: Ten patients admitted to the hospital with stable or unstable angina underwent phlebotomy prior to, three hours and six hours after administration of a standard oral loading dose of clopidogrel. The samples were then treated in vitro with incremental concentrations of tirofiban (0, 10, 20, 40, 60, and 80 ng/mL), and optical platelet aggregometry was performed utilizing ADP and TRAP as agonists. We analyzed the combined effects of these agents using a mixed effects model with time and tirofiban concentration as fixed effects, and subject and timing of phlebotomy as random effects. RESULTS: There was no evidence of additional inhibition of platelet aggregation due to clopidogrel regardless of the concentration of tirofiban or the study agonist (ADP 20 muM or iso-TRAP). Specifically, there was no difference in the tirofiban dose-response curves with either platelet agonist for any of the three time points (before, and three and six hours after, clopidogrel administration). DISCUSSION: There is no evidence that the combination of clopidogrel and tirofiban achieves greater inhibition of platelet aggregation than tirofiban alone.


Subject(s)
Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation/drug effects , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Ticlopidine/analogs & derivatives , Ticlopidine/administration & dosage , Tyrosine/analogs & derivatives , Tyrosine/administration & dosage , Aged , Aged, 80 and over , Angina Pectoris/blood , Angina Pectoris/drug therapy , Clopidogrel , Drug Combinations , Drug Interactions/physiology , Female , Humans , Male , Middle Aged , Platelet Aggregation/physiology , Platelet Glycoprotein GPIIb-IIIa Complex/metabolism , Tirofiban
18.
J Am Coll Cardiol ; 42(2): 234-40, 2003 Jul 16.
Article in English | MEDLINE | ID: mdl-12875757

ABSTRACT

OBJECTIVES: We sought to determine the frequency and timing of complications at our institution when surgery was performed within two months of coronary stent placement. BACKGROUND: The optimal delay following coronary stent placement prior to non-cardiac surgery is unknown. METHODS: We analyzed the Mayo Clinic Percutaneous Coronary Intervention and Surgical databases between 1990 and 2000 and identified 207 patients who underwent surgery in the two months following successful coronary stent placement. RESULTS: Eight patients (4.0%) died or suffered a myocardial infarction or stent thrombosis. All 8 patients were among the 168 patients (4.8%, 95% confidence interval [CI] 2.1 to 9.2) undergoing surgery six weeks after stent placement; the frequency of these events ranged from 3.8% to 7.1% per week during each of the six weeks. No events occurred in the 39 patients undergoing surgery seven to nine weeks after stent placement (0%, 95% CI 0.0 to 9.0). CONCLUSIONS: These data suggest that, whenever possible, non-cardiac surgery should be delayed six weeks after stent placement, by which time stents are generally endothelialized, and a course of antiplatelet therapy to prevent stent thrombosis has been completed.


Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Coronary Disease/complications , Coronary Disease/therapy , Coronary Thrombosis/etiology , Myocardial Infarction/etiology , Postoperative Hemorrhage/etiology , Stents/adverse effects , Surgical Procedures, Operative/adverse effects , Aged , Anticoagulants/therapeutic use , Aspirin/therapeutic use , Blood Transfusion/statistics & numerical data , Coronary Angiography , Coronary Thrombosis/epidemiology , Coronary Thrombosis/prevention & control , Female , Humans , Male , Middle Aged , Minnesota/epidemiology , Myocardial Infarction/epidemiology , Myocardial Infarction/prevention & control , Platelet Aggregation Inhibitors/therapeutic use , Postoperative Hemorrhage/epidemiology , Postoperative Hemorrhage/prevention & control , Pyridines/therapeutic use , Retrospective Studies , Time Factors , Treatment Outcome , Warfarin/therapeutic use
19.
Rev Cardiovasc Med ; 3(2): 67-70, 2002.
Article in English | MEDLINE | ID: mdl-12447149

ABSTRACT

The IIb/IIIa receptor inhibitors have been shown to improve outcomes following percutaneous coronary intervention (PCI), particularly by decreasing periprocedural myocardial necrosis. Abciximab has been subject to multiple studies, demonstrating consistent improved early and late outcomes in multiple patient populations, including a mortality advantage in diabetics, but there has been concern about the possibility of anaphylaxis, thrombocytopenia, and reduced clinical efficacy with repeat administration of abciximab. Results of the ReoPro Readministration Registry, a prospective, phase IV, multicenter registry of 500 patients undergoing PCI who were treated with abciximab at least 7 days after a previous treatment with this same drug, support the contention that abciximab readministration is both safe and clinically efficacious and that there is no significant increase in the incidence of thrombocytopenia as compared with historical controls of trials of first abciximab administration. However, profound thrombocytopenia did occur with increased frequency as compared with historical controls, suggesting a shift from mild to profound thrombocytopenia with abciximab readministration.


Subject(s)
Antibodies, Monoclonal/adverse effects , Coronary Disease/drug therapy , Immunoglobulin Fab Fragments/adverse effects , Platelet Aggregation Inhibitors/adverse effects , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Thrombocytopenia/chemically induced , Abciximab , Angioplasty, Balloon, Coronary , Antibodies, Monoclonal/administration & dosage , Clinical Trials, Phase IV as Topic , Coronary Disease/therapy , Humans , Immunoglobulin Fab Fragments/administration & dosage , Platelet Aggregation Inhibitors/administration & dosage , Treatment Outcome
20.
J Invasive Cardiol ; 14(12): 720-4, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12454332

ABSTRACT

UNLABELLED: A number of evolving clinical indications for cutting balloon angioplasty (CBA) have been described in the clinical literature, including angioplasty-resistant stenoses, in-stent restenosis, ostial lesions and small vessel disease. METHODS: We analyzed the Mayo Clinic PTCA registry and report procedural and in-hospital clinical outcomes in 100 patients (103 procedures, 114 lesions) undergoing CBA. RESULTS: CBA was successfully completed in 109 lesions (96%). The majority of lesions (73%) required additional treatment with either balloon angioplasty (39%) or stent implantation (34%). Severe intimal dissection resulting in at least 50% luminal obstruction occurred in 13 lesions (11%). A single incident of branch occlusion was documented, resulting in ST elevation myocardial infarction. There were no incidents of vessel perforation, urgent percutaneous or surgical target vessel revascularization, or in-hospital death. CONCLUSION: CBA is feasible and safe, with a low incidence of procedural complications and in-hospital adverse cardiac events when used primarily for in-stent restenosis.


Subject(s)
Angina, Unstable/therapy , Angioplasty, Balloon/instrumentation , Myocardial Infarction/therapy , Stents , Academic Medical Centers , Aged , Angina, Unstable/diagnostic imaging , Angioplasty, Balloon/methods , Coronary Angiography , Equipment Design , Equipment Safety , Female , Follow-Up Studies , Humans , Male , Middle Aged , Minnesota , Myocardial Infarction/diagnostic imaging , Prognosis , Registries , Retrospective Studies , Risk Assessment , Severity of Illness Index , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...